These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26955963)

  • 21. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
    Lu H; Li X; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Zibelman M; Mehra R
    Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting ERBB receptors shifts their partners and triggers persistent ERK signaling through a novel ERBB/EFNB1 complex.
    Vermeer PD; Colbert PL; Wieking BG; Vermeer DW; Lee JH
    Cancer Res; 2013 Sep; 73(18):5787-97. PubMed ID: 23811940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer.
    Byeon HK; Ku M; Yang J
    Exp Mol Med; 2019 Jan; 51(1):1-14. PubMed ID: 30700700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
    Karamouzis MV; Grandis JR; Argiris A
    JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck.
    Juergens RA; Bratman SV; Tsao MS; Laurie SA; Sara Kuruvilla M; Razak AR; Hansen AR
    Cancer Treat Rev; 2017 Mar; 54():43-57. PubMed ID: 28192747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
    Koch AT; Love-Homan L; Espinosa-Cotton M; Stanam A; Simons AL
    Cancer Res; 2015 Apr; 75(8):1657-67. PubMed ID: 25712126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Promising new molecular targeted therapies in head and neck cancer.
    Dorsey K; Agulnik M
    Drugs; 2013 Mar; 73(4):315-25. PubMed ID: 23440867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular pathways in head and neck cancer: EGFR, PI3K, and more.
    Psyrri A; Seiwert TY; Jimeno A
    Am Soc Clin Oncol Educ Book; 2013; ():246-55. PubMed ID: 23714515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer.
    Ugurluer G; Ozsahin M
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1637-54. PubMed ID: 25134724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.
    Kondo N; Tsukuda M; Taguchi T; Nakazaki K; Sakakibara A; Takahashi H; Toth G; Nishimura G
    Cancer Sci; 2011 Sep; 102(9):1717-23. PubMed ID: 21631644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.
    Mehra R; Cohen RB; Harari PM
    Curr Oncol Rep; 2008 Mar; 10(2):176-84. PubMed ID: 18377832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma.
    Kao J; Sikora AT; Fu S
    Curr Cancer Drug Targets; 2009 Dec; 9(8):931-7. PubMed ID: 20025602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance.
    Rebucci M; Peixoto P; Dewitte A; Wattez N; De Nuncques MA; Rezvoy N; Vautravers-Dewas C; Buisine MP; Guerin E; Peyrat JP; Lartigau E; Lansiaux A
    Int J Oncol; 2011 Jan; 38(1):189-200. PubMed ID: 21109940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications.
    Zimmermann M; Zouhair A; Azria D; Ozsahin M
    Radiat Oncol; 2006 May; 1():11. PubMed ID: 16722544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer.
    Herbst RS; Kim ES; Harari PM
    Expert Opin Biol Ther; 2001 Jul; 1(4):719-32. PubMed ID: 11727507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.
    Harari PM; Huang SM
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):427-33. PubMed ID: 11173137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.